News Picture Generic

Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets

June 6, 2019

Molecules Journal

Due to the lack of approved vaccines against human leishmaniasis and the limitations of the current chemotherapy inducing side effects and drug resistance, development of new, effective chemotherapeutic agents is essential. This study describes the synthesis of a series of novel oxadiazoles and indolizine-containing compounds. The compounds were screened in silico using an EIIP/AQVN filter followed by ligand-based virtual screening and molecular docking to parasite arginase. Top hits were further screened versus human arginase and finally against an anti-target battery to tag their possible interactions with proteins essential for the metabolism and clearance of many substances. Eight candidate compounds were selected for further experimental testing. The results show measurable in vitro anti-leishmanial activity for three compounds. One compound with an IC50 value of 2.18 µM on Leishmania donovani intramacrophage amastigotes is clearly better positioned than the others as an interesting molecular template for further development of new anti-leishmanial agents.

For details

Synthesis, In Silico, and In Vitro Evaluation of Anti-Leishmanial Activity of Oxadiazoles and Indolizine Containing Compounds Flagged against Anti-Targets

Strahinja Stevanovic 1, Milan Sencanski 1, Mathieu Danel 2, Christophe Menendez 3,4, Roumaissa Belguedj 3,4,5, Abdelmalek Bouraiou 5, Katarina Nikolic 6 , Sandrine Cojean 7, Philippe M. Loiseau 7, Sanja Glisic 1, Michel Baltas 3,4 and Alfonso T. García-Sosa 8

1 Laboratory for Bioinformatics and Computational Chemistry, Institute of Nuclear Sciences VINCA, University of Belgrade, P.O. Box 522, 11001 Belgrade, Serbia

2 ITAV, Université de Toulouse, CNRS, 31062 Toulouse, France

3 Department of Chemistry, Université de Toulouse, UPS, CNRS UMR 5068, LSPCMIB, 118 Route de Narbonne, 31062 Toulouse, France

4 CNRS, Laboratoire de Synthèse et Physico-Chimie de Molécules d’Intérêt Biologique, LSPCMIB, UMR-5068, 118 Route de Narbonne, 31062 Toulouse, France

5 Unité de Recherche de Chimie de l’Environnement et Moléculaire Structurale, Université Frères Mentouri, Route de Ain El Bey, 25000 Constantine, Algeria

6 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia

7 Antiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290 Chatenay-Malabry, France

8 Institute of Chemistry, University of Tartu, Ravila 14a, 50411 Tartu, Estonia

For more information about Chemspeed solutions:

ISYNTH SWAVE

ISYNTH AI

ISYNTH SPEEDCHEM

Molecules 2019, 24, 1282; doi:10.3390/molecules24071282

For details please contact [email protected]

Other Recent News

Discover more news articles you might be interested in

Read more about Altana tests coatings for the industry in a unique high-throughput facility worldwide / Altana testet Lacke fuer die Industrie in weltweit einmaliger Hochdurchsatzanlage
News Picture 1 1 V2
Featured
Jan
30

Altana tests coatings for the industry in a unique high-throughput facility worldwide / Altana testet Lacke fuer die Industrie in weltweit einmaliger Hochdurchsatzanlage

VDI news / nachrichten

Up to 220 paint samples per day go through a fully automated screening in a unique testing facility at Byk in Wesel. / Bis zu 220 Lackproben pro Tag durchlaufen ein vollautomatisches Screening in einer weltweit einmaligen Pruefanlage bei Byk in Wesel.

Read more about Asymmetric hydrogenation of olefins with transition metal-based catalysts: practical insights from screening to production of APIs
News Picture 1 1 V2
Featured
Jan
20

Asymmetric hydrogenation of olefins with transition metal-based catalysts: practical insights from screening to production of APIs

Selective hydrogenation plays a critical role in modern synthetic chemistry, particularly in the pharmaceutical industry, where the production of chiral molecules with high enantiomeric purity is essential for the efficacy and safety of active pharmaceutical ingredients (APIs). 

© Chemspeed Technologies 2026